# EP300

Source: https://onco.cc/targets/ep300/  
OnCo record `ep300` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EP300 (Histone acetyltransferase p300) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Bladder & urothelial cancer, Head and neck squamous cell carcinoma and 5 more.

## Summary

Functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.87 (direct and indirect evidence; datatypes affected pathway 0.82, literature 0.99, genetic association 0.69, somatic mutation 0.95, animal model 0.59). IntOGen calls it a driver in 30 cohorts (10 activating, 20 loss-of-function), covering Angiosarcoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Cervical Squamous Cell Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: EP300 lysine acetyltransferase; Histone acetyltransferase p300; p300; KAT3B
- Tags: cancer-genes-wave
- Symbol: EP300
- Class: transcription
- Biology: Functions as a histone acetyltransferase and regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Histone acetylation gives an epigenetic tag for transcriptional activation. Mediates acetylation of histone H3 at 'Lys-122' (H3K122ac), a modification that localises at the surface of the histone octamer and stimulates transcription, possibly by promoting nucleosome instability. Mediates acetylation of histone H3 at 'Lys-18' and 'Lys-27' (H3K18ac and H3K27ac, respectively). Also able to acetylate histone lysine residues that are already monomethylated on the same side chain to form N6-acetyl-N6-methyllysine (Kacme), an epigenetic mark of active chromatin associated with increased transcriptional initiation. Location: Cytoplasm; Nucleus; Chromosome (UniProt). Locus 22q13.2 (HGNC).
- Where found: Colorectal cancer: Open Targets association 0.74 with colorectal cancer (MONDO_0005575); IntOGen driver in 1 cohort (COADREAD); Bladder & urothelial cancer: Open Targets association 0.65 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLCA, UTUC); Head and neck squamous cell carcinoma: Open Targets association 0.62 with head and neck squamous cell carcinoma (MONDO_0010150); IntOGen driver in 3 cohorts (HNSC); Non-Hodgkin lymphoma: Open Targets association 0.62 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Lung cancer: Open Targets association 0.62 with lung cancer (MONDO_0008903); Cervical cancer: Open Targets association 0.60 with cervical cancer (MONDO_0002974); IntOGen driver in 3 cohorts (CESC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 10 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 20 cohorts; CIViC holds 2 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3373: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3373
- UniProt Q09472: https://www.uniprot.org/uniprotkb/Q09472/entry
- NCBI Gene 2033: https://www.ncbi.nlm.nih.gov/gene/2033
- Ensembl ENSG00000100393: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100393

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- pathways: [Prostate cancer (KEGG map)](https://onco.cc/pathways/prostate-cancer-signalling/), [Transcriptional machinery & addiction](https://onco.cc/pathways/transcription-addiction/)

---
JSON: https://onco.cc/api/v1/entities/ep300.json